The global pulmonary arterial hypertension (PAH) treatment market is projected to grow from USD 5,811.5 million in 2023 to USD 7,224.4 million by 2033, expanding at a CAGR of 2.2% over the forecast period. The market’s steady growth is driven by increased awareness, improved accessibility to treatments, and the integration of complementary therapies alongside traditional pharmaceuticals. Pulmonary …